-
*Dawn Buse, MD, PhD Diagnosis, Burden and Comorbidity of Migraines TMigraine is a common, chronic neurologic disease with episodic manifestations known as migraine attacks. Migraine can be associated with significant disability both during attacks as well as globally and has a range of comorbidities. The goal of this course is to provide an overview of the diagnostic criteria, burden and known migraine comorbidities as well as provide clinical insights into the diagnosis and management of migraine using a case example. 1 AMA PRA Category 1 Credit ™
-
*Peter Goadsby, Md, PhD, FAHS Insights into the Genetics and Pathophysiology of Migraine This educational course will outline the inherited basis of migraine insofar as it is currently understood. In order to understand and order treatment strategies, the module will outline the trigeminocervical anatomy and physiology and its interaction with cranial autonomic outflow pathway. The facilitates understanding many of the phenotypic manifestations of migraine that, when documented, facilitate the diagnosis. Non-headache symptoms that occur in the premonitory (prodromal) phase can be understood through an explanation of the known biology that again facilitates the clinical interaction and enhances management. 1 AMA PRA Category 1 Credit ™
-
*Jessica Ailani, MD Advances in the Preventive Treatment of Migraine This session will discuss the use of preventive treatment in migraines. It will review when to discuss preventive strategies in patients with migraine and how to integrate discussions about lifestyle changes, behavioral management, and pharmacological preventive treatments in reaching a patient's goals of care. This talk will review new treatments in migraine prevention and how to use shared decision making when choosing prevention. 1 AMA PRA Category 1 Credit ™
-
*Richard B. Lipton, MD Advances in Acute Treatment of Migraine and New Paradigms of Treatment This lecture will summarize recently approved acute treatments for migraine, including newer molecular entities such as gepants, (CGRP small molecule receptor blockers) and ditans (5HT1f receptor agonists), as well as new takes on older medications including novel formulations of NSAIDs, triptans, dihydroergotamine and combination products. We will consider an approach to prioritizing and individualizing acute treatments based on patient needs. Next, we will consider the opportunities created when the same agent can be used as both an acute and as a preventive treatment. These opportunities include simultaneously using the same medication as both a preventive treatment and as an acute treatment as well as shifting between acute and preventive treatment for a particular patient based on treatment needs. In addition, early treatment approaches include treating while pain is mild, treating during the prodrome, and treating in periods of increased short-term risk of headache before symptoms develop (situational prevention). 1 AMA PRA Category 1 Credit ™
